Daclizumab News
Reduced Exposure to Calcineurin Inhibitors in Renal Transplantation
Background: Immunosuppressive regimens with the fewest possible toxic effects are desirable for transplant recipients. This study evaluated the efficacy and relative toxic effects of four immunosuppressive regimens.
Roche Gives Up Daclizumab; PDL Seeking Asthma Partner
Hoffmann-La Roche Inc.'s decision to back out entirely of the deal with PDL BioPharma Inc. for Zenapax (daclizumab) leaves intact the biotech firm's main revenue sources - as well as a separate pact with Biogen Idec to develop...
Micromet Presents New Anti-IL-2 Antibody with Unique Mode of Action
Potential against Inflammatory Diseases, T Cell Leukemia and Transplant Rejection
Zenapax (daclizumab): Hopes raised for effectiveness of multiple sclerosis drug
A national research team led by the University of Cincinnati's Bibiana Bielekova, MD, report new insights into how anti-rejection drug helps MS patients.
Research: Daclizumab Method of Action Surprises Researchers
Biogen's Daclizumab has recently surprised researchers with its method of action. Daclizumab, known in the market as Zenapax, is a drug currently used to prevent the rejection of organ transplants, particularly the kidney.